Anavex Life Sciences has recently released its 10-K report, detailing its operations and financials. The company, headquartered in New York, is a clinical stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease, Parkinson's disease, and other central nervous system diseases, including rare diseases such as Rett syndrome, infantile spasms, Fragile X syndrome, and Angelman syndrome. Additionally, the company's drug candidate, ANAVEX 3-71, is in clinical trials for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Anavex also has preclinical drug candidates, including ANAVEX 1-41 for the treatment of depression, stroke, and neurodegenerative diseases, ANAVEX 1066 for potential treatment of neuropathic and visceral pain, and ANAVEX 1037 to treat prostate and pancreatic cancer.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
As of December 23, 2024, the beneficial ownership of Anavex's common stock was as follows: Christopher Missling, the CEO and Director, held 7,363,264 shares, representing 8.1% of the class. Jiong Ma, Director and Chair, held 110,000 shares. Claus van der Velden, Director, held 255,500 shares. Athanasios Skarpelos, Director, held 1,611,958 shares. Steffen Thomas, Director, held 360,500 shares. Peter Donhauser, Director, held 260,500 shares. Sandra Boenisch, Principal Financial Officer, held 275,262 shares. Collectively, the Directors & Executive Officers as a group held 10,236,984 shares, amounting to 11.1% of the class.
Additionally, significant 5% holders included The Vanguard Group, holding 4,360,648 shares, and BlackRock, Inc., holding 6,671,075 shares.
The report also detailed the 2022 Stock Option Plan, wherein the Board approved the 2022 Omnibus Incentive Plan, making 10,000,000 shares of Common Stock available for issuance under the plan. As of September 30, 2024, there were 22,050,553 securities to be issued upon the exercise of outstanding options, warrants, and rights, with a weighted-average exercise price of 7.02. There were 5,462,202 securities remaining available for future issuances under equity compensation plans.
Anavex Life Sciences' 10-K report provides a comprehensive overview of its ownership structure and equity compensation plans, shedding light on the company's share ownership and incentive programs. Today the company's shares have moved 8.7% to a price of $12.16. For more information, read the company's full 10-K submission here.
